NCT05271162View on ClinicalTrials.gov

Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines

PHASE3RecruitingINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

September 30, 2023

Primary Completion Date

January 1, 2028

Study Completion Date

February 1, 2028

Conditions
Cardiotoxicity
Interventions
DRUG

Empagliflozin 10 MG

Empagliflozin 10 mg q.d; p.o

OTHER

Placebo

Placebo 1 tabl q.d; p.o

Trial Locations (2)

Unknown

NOT_YET_RECRUITING

Institute of Hematology and Transfusion Medicine, Warsaw

RECRUITING

National Institute of Oncology, Warsaw

Sponsors
All Listed Sponsors
collaborator

Medical Research Agency, Poland

OTHER_GOV

lead

Maria Sklodowska-Curie National Research Institute of Oncology

OTHER

NCT05271162 - Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines | Biotech Hunter | Biotech Hunter